Hani Gabra
Imperial College London,UK
Title: Understanding the molecular basis of clinically acquired platinum resistance (APR) in ovarian cancer (OC): Strategies for the clinic
Biography
Biography: Hani Gabra
Abstract
To identify therapeutic strategies for circumventing APR in OC, we utilised isogenically matched cell lines from platinum sensitive patients who then developed APR to undertake RNA expression microarray analysis to identify genes upregulated in APR. SiRNA knockdown revealed targets whose downregulation re-sensitised cells to platinum. Preclinical development identified that AKT and DNA-PK where strong candidates for inhibition strategies. A clinical phase Ib/II trial demonstrated a 40% RECIST response rate in APR patients receiving carboplatin and paclitaxel 3 weekly, in whom a response rate of <13% would be expected. This approach opens up new possibilities for treatment of recurrent OC.